Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients With High-Risk Cytogenetics: IKEMA Subgroup Analysis

Expert hematologist-oncologist Thomas G. Martin, MD, shares data from the IKEMA subgroup analysis in patients with relapsed multiple myeloma treated with isatuximab, carfilzomib, and dexamethasone.

Related Videos
Related Content

Patient Assessment Drives Treatment Advances in Multiple Myeloma

February 6th 2023

Expert and Patient Perspectives on Comprehensive Multiple Myeloma Treatment

December 22nd 2022

Updated MAIA Data Show D-Rd Maintains Survival Benefit Over Rd in Transplant-Ineligible, Newly Diagnosed Myeloma

January 29th 2023

Mikhael and Cole Share Insights on Culturally Relevant Myeloma Care

October 27th 2022

KRd Improves PFS as Maintenance Therapy in Transplant-Eligible Multiple Myeloma

January 25th 2023

Ide-cel Elicits Durable Responses in High-risk Myeloma After Inadequate ASCT Response

January 24th 2023

Patient Assessment Drives Treatment Advances in Multiple Myeloma

February 6th 2023

Expert and Patient Perspectives on Comprehensive Multiple Myeloma Treatment

December 22nd 2022

Updated MAIA Data Show D-Rd Maintains Survival Benefit Over Rd in Transplant-Ineligible, Newly Diagnosed Myeloma

January 29th 2023

Mikhael and Cole Share Insights on Culturally Relevant Myeloma Care

October 27th 2022

KRd Improves PFS as Maintenance Therapy in Transplant-Eligible Multiple Myeloma

January 25th 2023

Ide-cel Elicits Durable Responses in High-risk Myeloma After Inadequate ASCT Response

January 24th 2023

Patient Assessment Drives Treatment Advances in Multiple Myeloma

February 6th 2023

Expert and Patient Perspectives on Comprehensive Multiple Myeloma Treatment

December 22nd 2022

Updated MAIA Data Show D-Rd Maintains Survival Benefit Over Rd in Transplant-Ineligible, Newly Diagnosed Myeloma

January 29th 2023

Mikhael and Cole Share Insights on Culturally Relevant Myeloma Care

October 27th 2022

KRd Improves PFS as Maintenance Therapy in Transplant-Eligible Multiple Myeloma

January 25th 2023

Ide-cel Elicits Durable Responses in High-risk Myeloma After Inadequate ASCT Response

January 24th 2023
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact